Northstar Neuroscience (NSTR) Board to Review Tang Capital's Unsolicited Offer
More News related to NSTR
- Northstar Neuroscience Announces Management Promotion
- Northstar Neuroscience, Inc. Announces Revisions to its Strategic Plan and Reports Financial Results for the Second Quarter of 2008
- Northstar Neuroscience Schedules Second Quarter 2008 Earnings Release and Conference Call for Thursday, July 31, 2008; Acknowledges Letter from RA Capital Management
- Vertos Medical Inc. Completes Series C Financing
- RA Capital Biotech Fund, LP Urges Board of Northstar Neuroscience, Inc. to Maximize Value to Shareholders by Reducing Expenses and Either Finding a Buyer or Making a Cash Distribution
More News related to Mergers and Acquisitions
- Manitowoc (MTW) and Enodis plc Receive Antitrust Clearance from DOJ for Proposed Acquisition
- China Medical Technologies (CMED) to Acquire HPV-DNA Biosensor Chip and SPR-based Analysis System for $345M
- Rodman & Renshaw Re-Initiates Coverage on DUSA Pharmaceuticals (DUSA) with a Market Outperform, Sees as Possible Takeover Target
- Wachovia, Citigroup, and Wells Fargo Announce Litigation Standstill
- IAMGOLD (IAG) Sends Offer to Acquire Euro Ressources
Responding to an unsolicited proposal from Tang Capital Partners for $2.25 per share, Northstar Neuroscience, Inc., (NASDAQ: NSTR) today announced that its Board will review and consider the offer consistent with its fiduciary duties. The Company also announced that the Board has engaged Leerink Swann to assist in the evaluation of strategic alternatives.
Northstar Neuroscience, Inc., a medical device company, focuses on the development and commercialization of neurostimulation solutions for various neurological diseases and disorders.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
